Factor V Leiden Mutation and Thromboembolism Risk in Women Receiving Adjuvant Tamoxifen for Breast Cancer

BACKGROUND: Tamoxifen use has been associated with increased risk of thromboembolic events (TEs) in women with breast cancer and women at high risk for the disease. Factor V Leiden (FVL) is the most common inherited clotting factor mutation and also confers increased thrombosis risk. We investigated...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Garber, Judy E., Halabi, Susan, Tolaney, Sara M., Kaplan, Ellen, Archer, Laura, Atkins, James N., Edge, Stephen, Shapiro, Charles L., Dressler, Lynn, Paskett, Electra M., Kimmick, Gretchen, Orcutt, James, Scalzo, Anthony, Winer, Eric, Levine, Ellis, Shahab, Nasir, Berliner, Nancy
التنسيق: Artigo
اللغة:Inglês
منشور في: Oxford University Press 2010
الموضوعات:
Articles
الوصول للمادة أونلاين:https://ncbi.nlm.nih.gov/pmc/articles/PMC2897879/
https://ncbi.nlm.nih.gov/pubmed/20554945
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djq211
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة